Help Change The Future of Medicine

We are actively recruiting research participants in paid clinical trials. StarMed Healthcare has been involved in proving the safety and effectiveness of medications ranging from Diabetes care to Meningitis prevention to COVID-19 treatments. With our experienced research team, you can feel confident in the safety and success of the trials.

Our Active Studies.

Moderna KidCove Vaccine

Study Drug: Moderna COVID-19 Vaccine
An FDA approved for Emergency Use Authorization (EUA) vaccine for adults, Moderna is now testing the safety and efficacy for children under the age of 12.

This study does include the possibility of receiving a placebo.

CURRENTLY ACCEPTING CHILDREN AGES 6 MONTHS TO UNDER 5 YEARS ONLY.

Study Design: “Kid Cove” is a study designed for vaccinating children under the age of 12 with lower dosing. The objective of this study is to determine the safety and effectiveness of their vaccine for children and prevent the spread of COVID-19 in those of young age.

Number of Visits: 7 Clinic visits, 2 Telemedicine visits, and a monthly phone visit.

You may be compensated for your time and travel.

*** When you send your email by clicking the button below, please be sure to include: Number of children with each child(s) age you would like to enroll, whether or not your child has had a previously confirmed COVID-19 diagnosis, child(s) ethnicity and the best phone number where we can reach you.

Revive Therapeutics-RT003

Study Drug: Bucillamine
Revive Therapeutics-RT003A safe anti inflammatory drug previously used for Rheumatoid Arthritis in several countries with great success. Revive Therapeutics is testing the safety and efficacy of Bucillamine in COVID-19.

This study does include the possibility of receiving a placebo.

Study Design: Once a patient has tested positive for COVID-19 they will begin the screening/randomization process of the study. Upon completion, the patient will receive the study drug (Bucillamine) or a possible placebo. The objective of this study is alleviate symptoms of COVID-19 and prevent hospitalization.

Number of Visits: 14 visits for the first two weeks, 7 In-Patient and 7 Telemedicine. 3 follow up visits over the course of up to 74 days.

ELI-LILLY “BLAZE”

Study Drug: J2X-MC-PYAH
Eli-Lilly is testing the safety and efficacy of an interventional drug for COVID-19. A one-time therapeutic infusion composed of monoclonal antibodies to fight off the negative effects of COVID-19.

This study does include the possibility of receiving a placebo.

Study Design: Once a patient has tested positive for COVID-19 they will begin the screening/randomization process of the study. Upon completion, the patient will receive a one-time infusion to alleviate the COVID-19 symptoms being displayed. The objective of this study is to prevent the illness from getting worse or hospitalization.

Number of Visits: 7 clinic visits, 6 Telemedicine visits lasting up to 84 days.

Astra Zeneca “Tackle”

Study Drug: AZD7442
Astra Zeneca is testing the safety and efficacy of an interventional drug for COVID-19. AZD7442, administered through an injection, is composed of 2 monoclonal antibodies used to alleviate COVID-19 symptoms.

This study does include the possibility of receiving a placebo.

Study Design: Once a patient has tested positive for COVID-19 they will begin the screening/randomization process of the study. The study is designed to help patients who are considered to be high risk. The patient will receive two injections of AZD7442 to help alleviate COVID-19 symptoms and prevent hospitalization.

Number of Visits: 10 visits over 29 days.

Sagent Pharmaceuticals “Camelot”

Study Drug: Comostat Mesilate
Sagent Pharmaceuticals tested the safety and efficacy of a COVID-19 experimental drug for the relief of symptoms related to the virus. Camostat Mesilate has been previously used for patients suffering from chronic pancreatitis and post-operative reflux esophagitis.

This study does include the possibility of receiving a placebo.

Study Design: Once the patient tested positive for COVID-19 they began the screening and randomization process of the study. The objective of this study was to see the decrease in COVID symptoms in positive patients. The participant was seen in the office every seven days for a period of 28 days. At the end of the study over 15 patients were randomized.

LaRoche Pediatric Flu/Influenza

Study Drug: Baloxavir Marboxil
Baloxavir Marboxil exerts antiviral effects against influenza. It is a prodrug that is converted into an active form in the blood, liver, and small intestine through hydrolysis. It was first approved in the USA in 2018 for those over the age of 12 who were symptomatic for less than 48 hours.

This study does include the possibility of receiving a placebo.

Study Design: A Phase Two clinical trial designed to study the safety and efficacy of Baloxavir Marboxil in patients under the age of 1. Its objective was to alleviate symptoms of the flu once they are first displayed. The patient would begin a screening and randomization period (Day 1) and then have mandatory visits on days 2, 4,6,10, and 29. The total duration of the study was 29 days.